Matrix Pharmaceutical plans to file New Drug Application (NDA) for AccuSite this month:
This article was originally published in Clinica
Matrix Pharmaceutical plans to submit a New Drug Application for its AccuSite injectable gel in the US before the end of September. The company has filed a Marketing Authorisation Application for the product in the UK. Contrary to allegations by Collagen, which Matrix faces in a suit filed in January, Matrix says that neither of its regulatory submissions references any of Collagen's PMA approval files.